Joint Stock Company Grindeks is an international, vertically integrated pharmaceutical company in the Baltic States, Latvia. The main fields of action are research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients. Portfolio of «Grindex» products are created by the successful combination of brand products and generic medications that are relevant to the highest requirements of safety and quality. «Grindex» offers more than 100 effective and safe medications – heart and cardiovascular, psychotropic, anti-cancer agents, CNS drugs, analgesic, cough and flu medications. Company is especially proud for its brand products Mildronate® and Ftorafur®.
«Grindex» also manufactures high quality active pharmaceutical ingredients for both the «Grindex» final dosage forms plant and for export to clients abroad.
Products are exported to more than 40 countries; export comprises more than 96% of the total turnover. The main markets are the Baltic States, Russia and other CIS countries, Japan, USA.
«Grindex» was the first pharmaceutical manufacturer in Latvia to have received the Good Manufacturing Practice (GMP) certificate issued by the State Pharmaceutical Agency.
Invariably «Grindex» maintains leading positions in the pharmaceutical market of Baltic States. Its representative offices and agents are working in 14 countries – Lithuania, Estonia, Russia, Kazakhstan, Georgia, Azerbaijan, Uzbekistan, Ukraine, Belarus, Moldova, Poland, Hungary, Czech Republic and Finland. Company products are being exported to more than 40 countries all over the world.
The manufacturing of pharmaceutical products is one of the most responsible spheres of manufacturing, because it is linked to human life and health and, therefore, the pharmaceutical industry is subject to extremely high quality requirements.
